U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444437) titled 'LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer' on Feb. 26.
Brief Summary: After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.
Study Start Date: Feb. 26
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
BIOLOGICAL: LM103 TILs Inje...